Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Bulk drug imports from...

Bulk drug imports from China increased from 62 percent to 75 percent in past 9 years: Report

Written by Ruchika Sharma Published On 7 Aug 2023 8:00 AM  |  Updated On 7 Aug 2023 8:00 AM
Bulk drug imports from China increased from 62 percent to 75 percent in past 9 years: Report
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Interestingly, of the total bulk drugs manufactured, almost one-third is exported, and the remaining two-thirds are domestically sold.

Mumbai: Bulk drug imports from China increased from 62 per cent to 75 per cent in the past nine years and India continues to depend on Chinese shipments despite commissioning of various domestic manufacturing projects under the government's production-linked incentive scheme, a report said. According to a report by Care Ratings, imports of bulk drug from China have soared in terms of both value as well as volume from 64 and 62 per cent in FY14 to 71 and 75 per cent in FY23, respectively.

In value terms, during FY14 to FY23, the country's total bulk drug imports from China increased at a compounded annual growth rate of about 7 per cent, indicating that the country continues to rely heavily on its northern neighbour for some of the critical key starting materials (KSMs), said Ranjan Sharma, a senior director with Care Ratings.
In FY14, the country imported a total of USD 5.2 billion of pharma, of which as much as USD 2.1 billion came in from China. The numbers rose to USD 6.4 billion and USD 2.6 billion, respectively in FY19, and further to USD 7 billion and USD 2.9 billion, respectively in FY21.
The northward movement continued in FY22 to USD 8.5 billion and USD 3.2 billion, respectively. The total inbound shipments marginally declined to USD 7.9 billion in FY23. However, the Chinese share jumped to USD 3.4 billion during that period, said Pulkit Agarwal, another director with the agency.
Bulk drugs emerged as the dominant component of imports, contributing 55-60 per cent of India's total pharma imports over the past decade.
Simultaneously, bulk drug imports have seen a steady compound annualised growth of about 7 per cent, reflecting the industry's growing reliance on shipments from abroad.
Besides, a significant portion of the country's pharma imports, including that of certain formulations, ayush and herbal, and surgical products, are sourced from various countries.
According to V Naveen Kumar, an associate director of the agency, the massive dependence on China is going on in spite of the commissioning of many bulk drug projects under the production-linked incentive (PLI) scheme along with backward integration being undertaken by various domestic pharma companies, which were launched to reduce the dependence on China to an extent.
In FY24, it is estimated that projects worth USD 516 million are expected to be commissioned under the PLI scheme. But the agency believes that despite commissioning of various projects under the PLI scheme, the dependency on bulk drug imports from China will remain high at about 65 per cent for many more summers.
The domestic pharmaceutical industry has demonstrated impressive growth over the years, achieving an annual growth of around 7 per cent during FY14-FY23. As of FY23, the industry's market size has soared to around USD 49.8 billion. Concurrently, the total pharma imports have also exhibited a similar annualised growth of about 7 per cent to USD 7.9 billion in FY23.
Of the overall imports, bulk drugs hold a significant share accounting for around 55 per cent, followed closely by formulations at 30-35 per cent, and the rest comprising ayush & herbal and surgical products.
Interestingly, of the total bulk drugs manufactured, almost one-third is exported, and the remaining two-thirds are domestically sold.
The country's contribution to the global supply of generic drugs is noteworthy, constituting about 20 per cent of the global supply.
The country's prowess in the pharma domain is further solidified by its rankings as the third largest in terms of volume and the 14th largest in terms of value. However, this position as a prominent supplier of generic drugs also entails a substantial demand for bulk drugs.
There are over 3,000 bulk drug manufacturers in the country but a majority of them are small unorganised players contributing 50-60 per cent of the total share.
Overall, China accounts for around 43 per cent of the total pharma imports, making it the primary source of bulk drugs for the industry. While imports of other pharma products are diversified across multiple countries, the reliance on China for bulk drugs stands out as a critical point of vulnerability.
The implications of such reliance on China for bulk drugs are far-reaching, particularly for life-saving drugs, where the dependency on key starting materials exceeds 50 per cent, raising legitimate concerns about the availability, cost, and uninterrupted supply of crucial medicines.
The spike is in spite of the domestic industry commissioning a record number of new plants during this period. In FY24 alone, total project completions worth USD 516 million in the drugs and pharmaceuticals industry are expected, which is the highest in the last decade. One of the prime reasons for such a high run rate of project completions is the PLI scheme introduced along with an overall increase in demand for drugs and pharmaceuticals.
During FY24 and FY25, the domestic industry is expected to grow by 7-9 per cent, which may lead to incremental requirements for APIs (active pharmaceutical ingredients), which are expected to be met through enhanced capacity additions under the PLI schemes. As a result, the overall dependency on the import of bulk drugs from China is likely to continue to be high, warns Kumar.
Over the past decade owing to unattractive business prospects and lower returns on investment for KSMs and APIs, the investments in these segments were weak. Simultaneously, on account of the availability of the said raw materials at lower prices from China, the domestic players have relied heavily on import of bulk drugs from China.
The PLI scheme although is supposed to play a critical role to develop KSMs and APIs at competitive prices and reduce dependency, the results of the same have not been very encouraging and the industry believes that combating the pricing war with Chinese players is extremely challenging, Kumar added.
Read also: Bulk Drug Park to change Pharma ecosystem of Himachal Pradesh
production linked incentive schemePLI schemeCare Ratingsbulk drug
Source : PTI
Ruchika Sharma
Ruchika Sharma
    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok